We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+32.47%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$6.66B
AUM Growth
+$1.54B
Cap. Flow
+$235M
Cap. Flow %
3.53%
Top 10 Hldgs %
47.3%
Holding
121
New
27
Increased
30
Reduced
28
Closed
12

Top Buys

Rank Stock Value
1
KARD
Kardigan Inc
KARD
+$190M
2
AVLN
Avalyn Pharma
AVLN
+$77.2M
3
TNGX icon
Tango Therapeutics
TNGX
+$63.5M
4
RLAY icon
Relay Therapeutics
RLAY
+$63.2M
5
BIIB icon
Biogen
BIIB
+$52.8M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$209M
2
ASND icon
Ascendis Pharma A/S
ASND
+$85.9M
3
DAWN
Day One Biopharmaceuticals
DAWN
+$37.6M
4
DYN icon
Dyne Therapeutics
DYN
+$36.8M
5
ABVX
Abivax
ABVX
+$28.8M

Sector Composition

Rank Sector Weight
1 Healthcare 96.3%
2 Miscellaneous 3.58%
3 Financials 0.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTB
101
Connect Biopharma Holdings
CNTB
$122M
$1.89M 0.03%
792,696
– –
KPRX icon
102
Kiora Pharmaceuticals
KPRX
$11.3M
$1.15M 0.02%
+438,471
New +$1.1M
MDLN
103
Medline Inc
MDLN
$32.1B
$1.1M 0.02%
28,000
– –
ADMA icon
104
ADMA Biologics
ADMA
$2.15B
$952K 0.01%
113,765
-353,468
-76% -$3.22M
CPIX icon
105
Cumberland Pharmaceuticals
CPIX
$101M
$628K 0.01%
96,982
-99,996
-51% -$479K
XGN icon
106
Exagen
XGN
$183M
$534K 0.01%
114,893
– –
ENSC icon
107
Ensysce Biosciences
ENSC
$8.56M
$25.1K ﹤0.01%
86,666
– –
SRZNW
108
DELISTED
Surrozen Inc Warrant
SRZNW
$2.75K ﹤0.01%
166,666
– –
APLS
109
DELISTED
Apellis Pharmaceuticals
APLS
– –
-80,956
Closed -$3.26M
BLTE
110
Belite Bio
BLTE
$6.89B
– –
-151,979
Closed -$24.2M
CNTA
111
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-5,258,903
Closed -$209M
DAWN
112
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-1,755,799
Closed -$37.6M
DRUG
113
Bright Minds Biosciences
DRUG
$667M
– –
-377,544
Closed -$27.5M
IKT icon
114
Inhibikase Therapeutics
IKT
$352M
– –
-2,315,000
Closed -$3.89M
NBIX icon
115
Neurocrine Biosciences
NBIX
$16.1B
– –
-65,050
Closed -$8.57M
NMRA icon
116
Neumora Therapeutics
NMRA
$254M
– –
-5,104,097
Closed -$9.95M
OCUL icon
117
CALL
Ocular Therapeutix
OCUL
$2.34B
– –
-500,000
Closed -$4.24M
PTN
118
Palatin Technologies
PTN
$23.3M
– –
-61,945
Closed -$1.08M
IRD
119
Opus Genetics
IRD
$383M
– –
-1,835,842
Closed -$8.35M
EVMN
120
Evommune Inc
EVMN
$436M
– –
-448,350
Closed -$10.3M
1 2 3 4
5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
KGAL
K5 Global Advisor LLC Miami Beach, Florida $6.59B AUM
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's Q2 2026 Portfolio in Review

As of Q2 2026, Perceptive Advisors held 121 positions worth $6.66B, up 30% from $5.12B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Perceptive Advisors deployed $235M of net new capital in Q2 2026, opening 27 new positions and adding to 30 existing holdings. Its largest new stake was Kardigan Inc: 8,200,662 shares worth $196M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was Ascendis Pharma A/S, an estimated $85.9M trimmed.

  • Perceptive Advisors's largest Q2 2026 buy was Kardigan Inc: 8,200,662 shares worth $196M.
  • Perceptive Advisors added most to Tango Therapeutics in Q2 2026, an estimated $63.5M increase.
  • Perceptive Advisors's biggest Q2 2026 reduction was Ascendis Pharma A/S, cutting an estimated $85.9M.
  • Perceptive Advisors fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $209M.
  • Perceptive Advisors's ten largest holdings make up 47% of its $6.66B portfolio in Q2 2026.
  • Perceptive Advisors opened 27 new positions and closed 12 in Q2 2026.
  • Perceptive Advisors's portfolio value rose 30% quarter-over-quarter to $6.66B.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.